Apontis Pharma AG stock PB Ratio (=2.9) is close to 3-year high of 3.13.
The historical rank and industry rank for Apontis Pharma AG's PB Ratio or its related term are showing as below:
FRA:APPH'
s PB Ratio Range Over the Past 10 Years
Min: 0.64 Med: 2.42 Max: 63.14
Current: 2.9
During the past 7 years, Apontis Pharma AG's highest PB Ratio was 63.14. The lowest was 0.64. And the median was 2.42.
FRA:APPH's PB Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.825
vs FRA:APPH: 2.90
During the past 12 months, Apontis Pharma AG's average Book Value Per Share Growth Rate was 4.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -8.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 58.50% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Apontis Pharma AG was 107.70% per year. The lowest was -8.00% per year. And the median was 92.75% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Apontis Pharma AG PB Ratio Related Terms
Apontis Pharma AG PB Ratio Historical Data
* Premium members only.
The historical data trend for Apontis Pharma AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Apontis Pharma AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apontis Pharma AG PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Apontis Pharma AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Apontis Pharma AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Apontis Pharma AG (FRA:APPH) has a PB Ratio of 2.90 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Apontis Pharma AG and its competitors. This is 20% above median its historical median of 2.42. Over the past decade, Apontis Pharma AG's PB Ratio has ranged from 0.64 to 63.14.
Is Apontis Pharma AG's PB Ratio too high?
Apontis Pharma AG's current PB Ratio of 2.90 is 20% above median its 10-year median of 2.42. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 63.14. The Drug Manufacturers industry median PB Ratio is 1.83. Apontis Pharma AG's value of 2.90 is 58.9% above this industry median. Overall, Apontis Pharma AG has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Apontis Pharma AG's PB Ratio compare to ZTS and UTHR?
Apontis Pharma AG's PB Ratio of 2.90 can be compared against companies in the Drug Manufacturers industry. The industry median PB Ratio is 1.83. Apontis Pharma AG's value of 2.90 is 58.9% above this benchmark. Historically, Apontis Pharma AG's own PB Ratio has ranged from 0.64 to 63.14 over the past decade. While the company's 10-year median is 2.42 vs. the industry median of 1.83, Apontis Pharma AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apontis Pharma AG's current PB Ratio of 2.90 is 58.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Apontis Pharma AG and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apontis Pharma AG's current PB Ratio is 2.90, which is 20% above median its own 10-year median of 2.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apontis Pharma AG stock overvalued right now?
Apontis Pharma AG (FRA:APPH) has a current PB Ratio of 2.90. The stock's GF Value™ is €10.46, compared to a current price of €11.00 — trading 5.2% above its estimated fair value. The current PB Ratio is 2.90, which is 20% above median its 10-year median of 2.42 and 58.9% above the Drug Manufacturers industry median of 1.83. Apontis Pharma AG's overall GF Score™ is 17/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Apontis Pharma AG (FRA:APPH), the current PB Ratio is 2.90 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apontis Pharma AG (FRA:APPH) Overvalued in 2026?
Based on GuruFocus' analysis, Apontis Pharma AG stock appears to be overvalued.
The current stock price of €11.00 is trading 5.2% above its estimated GF Value™ of €10.46.
Key valuation signals for FRA:APPH:
PB Ratio: 2.90 (20% above median its 10-year median of 2.42)
GF Value™: €10.46 vs. price of €11.00 (5.2% above fair value)
Industry Position: 58.9% above the Drug Manufacturers median
No single metric tells the full story. See the FRA:APPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apontis Pharma AG is a pharmaceutical company specializing in single pills in Germany. single pills combine two to three generic active ingredients in a single dosage form. The company develops, promotes, and sells a broad portfolio of single pills and other pharmaceutical products, with a special focus on cardiovascular diseases. The company markets drugs in the disease areas of respiratory diseases and diabetes as part of co-marketing/co-promotion.
17GF Score
Get the complete analysis for FRA:APPH
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:APPH has been successfully added to your 
